Gogoulos Panagiotis P, Sideris Giorgos, Nikolopoulos Thomas, Sevastatou Electra K, Korres George, Delides Alexander
Second Ear, Nose, and Throat (ENT) Department, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, GRC.
Medicine Department, Aristotle University of Thessaloniki, Thessaloniki, GRC.
Cureus. 2023 Feb 10;15(2):e34850. doi: 10.7759/cureus.34850. eCollection 2023 Feb.
Otosclerosis, also known as otospongiosis, is a primary osteodystrophy of the otic capsule of the inner ear and one of the leading causes of deafness in adults. The rationale for medical therapy for otospongiosis is to slow down and eventually stop the phase of bone resorption. Conservative treatments include sodium fluoride (NaF), bisphosphonates, and other modern medicines. A systematic review of the existing and published articles and books until April 2021 has been conducted in Medscape, Google Scholar, PubMed, and other databases using appropriate terms. According to the results of the research, the administration of NaF for a period of at least six months stabilizes hearing thresholds (HTs), improves vestibular symptoms, and delays the worsening of tinnitus. The administration of bisphosphonates for a period of at least six months showed significant percentage differences in the improvement of hearing loss, dizziness, and tinnitus remission. In the already existing double-blind studies that were evaluated, groups of patients treated with bisphosphonates for at least 24 months showed greater stabilization of the mean air and bone conduction thresholds than groups of patients treated with a placebo. The new modern medications have not yet been widely administered clinically to draw useful conclusions, although the test results of some of their use are quite encouraging.
耳硬化症,也称为耳海绵化症,是内耳耳囊的一种原发性骨营养不良,也是成人耳聋的主要原因之一。耳海绵化症的药物治疗原理是减缓并最终停止骨吸收阶段。保守治疗包括氟化钠(NaF)、双膦酸盐和其他现代药物。截至2021年4月,已在Medscape、谷歌学术、PubMed和其他数据库中使用适当的检索词,对现有的已发表文章和书籍进行了系统综述。根据研究结果,至少服用六个月的NaF可稳定听力阈值(HTs),改善前庭症状,并延缓耳鸣恶化。服用至少六个月的双膦酸盐在改善听力损失、头晕和耳鸣缓解方面显示出显著的百分比差异。在已评估的现有双盲研究中,接受双膦酸盐治疗至少24个月的患者组比接受安慰剂治疗的患者组在平均气导和骨导阈值方面表现出更大的稳定性。尽管一些新现代药物的使用测试结果相当令人鼓舞,但它们尚未在临床上广泛应用以得出有用的结论。